21 completed, 6 active not recruiting, 5 terminated, 4 unknown. 42 Phase 1, 15 Phase 2.
Follow Carcinoma, Medullary: new trials by email Literature Review of Carcinoma, Medullary trials Research Report on Carcinoma, Medullary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 211At-MABG in Adults With Advanced Neuroendocrine Cancers 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma | Phase 1 | Not yet recruiting | University of Pennsylvania | 16 | 2026-12-01 | 2026-10-07 |
| Study of SNH-118110 in Advanced Solid Tumors SNH-118110 Soft Capsules - Solid Tumors | Phase 1 | Not yet recruiting | ScinnoHub Pharmaceutical Co., Ltd. | 240 | 2026-06-26 | 2026-06-16 |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors 225Ac-ETN029, 111In-ETN029 - Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Recruiting | Novartis Pharmaceuticals | 116 | 2025-10-16 | 2026-09-22 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma 68Ga-MGS5 - Medullary Thyroid Carcinoma | Phase 1 | Unknown | First Affiliated Hospital of Fujian Medical University | 20 | 2023-06-21 | 2024-07-25 |
| A Study of TY-1091 in Patients With Advanced Solid Tumors TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | TYK Medicines, Inc | 248 | 2023-04-24 | 2024-01-30 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| GFRα4 CAR T Cells in MTC Patients single dose of CART-GFRa4 cells, Fludarabine, Cyclophosphamide - Metastatic Medullary Thyroid Cancer, Recurrent Thyroid Gland Medullary Carcinoma | Phase 1 | Active not recruiting | University of Pennsylvania | 9 | 2021-08-19 | 2026-07-22 |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Shouyao Holdings (Beijing) Co. LTD | 184 | 2021-04-23 | 2023-04-12 |
| Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | Turning Point Therapeutics, Inc. | 41 | 2019-12-06 | 2024-06-13 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors BOS172738 - Advanced Nonhaematologic Malignancies | Phase 1 | Completed | Boston Pharmaceuticals | 117 | 2018-12-12 | 2023-10-30 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Rovalpituzumab tesirine, Dexamethasone - Malignant Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Terminated | AbbVie | 200 | 2016-09-23 | 2020-10-19 |
| Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC 111In-CP04, 111In-CP04 with co-administration of gelofusine/gelaspan - Medullary Thyroid Carcinoma | Phase 1 | Completed | Paola Anna Erba | 16 | 2016-08-01 | 2020-03-20 |
| 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. 177Lu-PP-F11N - Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2 | Phase 1 | Active not recruiting | University Hospital, Basel, Switzerland | 24 | 2015-04-01 | 2026-05-01 |
| ImmunoTEP for Patients With Medullary Thyroid Carcinoma. • TF2 and 68 Ga-IMP-288 - Medullary Thyroid Carcinoma | Phase 1 / Phase 2 | Completed | Nantes University Hospital | 25 | 2013-01-01 | 2022-07-26 |
Showing 20 of 42. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Thyroid Neoplasms (15) · Head and Neck Neoplasms (11) · Breast Neoplasms (10) · Colonic Neoplasms (10) · Salivary Gland Neoplasms (10) · Lung Neoplasms (9) · Neoplasms (8) · Thyroid Cancer, Papillary (8) · Breast Neoplasms, Male (7) · Carcinoma, Hepatocellular (7) · Carcinoma, Merkel Cell (7) · Carcinoma, Renal Cell (7) · Testicular Neoplasms (7)
Neoplasms, Ductal, Lobular, and Medullary (42) · Adenocarcinoma (41) · Carcinoma (41) · Carcinoma, Neuroendocrine (41) · Neoplasms by Histologic Type (41) · Neoplasms, Germ Cell and Embryonal (41) · Neoplasms, Glandular and Epithelial (41) · Neoplasms, Nerve Tissue (41) · Neuroectodermal Tumors (41) · Neuroendocrine Tumors (37) · Neoplasms (34) · Neoplasms by Site (29) · Endocrine System Diseases (25) · Endocrine Gland Neoplasms (24) · Digestive System Diseases (16)
vandetanib (5) · Capecitabine (2) · Everolimus (2) · Magnetic Resonance Spectroscopy (2) · Trastuzumab (2) · cabozantinib (2) · selpercatinib (2) · 4-boronophenylalanine-fructose (1) · Acetates (1) · Bortezomib (1) · Calcium Aluminosilicate (1) · Cyclophosphamide (1) · Dacarbazine (1) · Dexamethasone (1) · Docetaxel (1)
National Cancer Institute (NCI) (8) · Eli Lilly and Company (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · University of Pennsylvania (2) · AbbVie (1) · Boston Pharmaceuticals (1) · Case Comprehensive Cancer Center (1) · Duke University (1) · Exelixis (1) · First Affiliated Hospital of Fujian Medical University (1) · Garden State Cancer Center at the Center for Molecular Medicine and Immunology (1) · Genzyme, a Sanofi Company (1) · Hoffmann-La Roche (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (30) · Germany (6) · South Korea (6) · China (5) · France (5) · Canada (4) · Japan (4) · Spain (4) · Hong Kong (3) · Italy (3) · Netherlands (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Belgium (2)
Herbert K. Lyerly, MD (2) · Agustin Garcia (1) · Anthony W. Tolcher, MD (1) · Brigitte C Widemann, M.D. (1) · Charles Hsu, MD (1) · Christof Rottenburger, Dr. med. (1) · Cornelis J. A. Punt, MD, PhD (1) · Damian Wild, Prof Dr Dr (1) · Francoise Bodere, PhD, MD (1)
PMID 37934000, PMID 17985341, PMID 19372041, PMID 19602035, PMID 19735988, PMID 20145168, PMID 21367608, PMID 21606412, PMID 23489023, PMID 23676418, PMID 23766359, PMID 24617713, PMID 25086465, PMID 25117183, PMID 25900182, PMID 25972901, PMID 29187393, PMID 30297385, PMID 32372416, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35930972, PMID 35962206, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37265412, PMID 37282666, PMID 37916501, PMID 38009200, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39489747, PMID 39983053, PMID 40639400, PMID 41886723, PMID 42847673, PMID 42874021
2016 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1), P30CA016672 (1), P30CA043703 (1), R01CA300202 (1), R21CA094523 (1), U01CA062461 (1), U01CA062502 (1), U01CA076576 (1), UM1CA097452 (1)